COPD is a preventable and treatable lung disease characterized by persistent and progressive airflow limitation. PRISm, on the other hand, is a spirometry pattern that does not meet COPD diagnostic criteria despite symptoms and functional impairments, but requires maintenance. PRISm can predispose to the development of COPD and exacerbations, and can reduce exercise capacity by reducing respiratory function and oxygen consumption. There are no studies in the literature comparing respiratory muscle strength, peripheral muscle strength, and oxygenation in PRISm, COPD, and healthy individuals. Therefore, this study aimed to evaluate these parameters and compare them with healthy individuals.
Eligibility
Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
For the COPD group:
* Being \>40 years old,
* Being diagnosed with COPD,
* Being clinically stable,
* Volunteering to participate in the study.
For the PRISm group:
* Being \>40 years old,
* Being diagnosed with PRISm,
* Volunteering to participate in the study.
For the healthy control group:
* Being \>40 years old,
* Volunteering to participate in the study.
Exclusion Criteria:
For the COPD group:
* Having severe orthopedic, neurological, or cardiac diseases,
* Being in a COPD exacerbation,
* Having a comorbid lung disease,
* Being on clinically unstable medication,
* Voluntarily not participating in the study.
For the PRISm group:
* Being diagnosed with COPD,
* Having severe orthopedic, neurological, or cardiac diseases,
* Having a comorbid lung disease,
* Voluntarily not participating in the study.
For the healthy control group:
* Having a known chronic disease,
* Voluntarily not participating in the study.
Primary outcome measure(s)
Upper extremity exercise capacity — Baseline Upper extremity exercise capacity will be evaluated with the six-minute pegboard and ring test (6-PBRT).
Lower extremity exercise capacity — Baseline Lower extremity exercise capacity will be evaluated with six- minute walking test.
Peripheral muscle strength — Baseline Peripheral muscle strength will be evaluated with a dynamometer.
Muscle oxygenation — Baseline Muscle oxygenation assessment will be performed using the Moxy monitor (Moxy, Fortiori Design LLC, Minnesota, USA).
Respiratory Muscle Strength — Baseline Maximal inspiratory (MIP) and maximal expiratory (MEP) pressures expressing respiratory muscle strength will be evaluated.
Respiratory Muscle Endurance — Baseline Respiratory muscle endurance will be assessed by the POWERbreathe Wellness (POWERbreathe, Inspiratory Muscle Training (IMT) Technologies Ltd., Birmingham, UK) device and the respiratory muscle endurance test at increased threshold load.
Dyspnea — Baseline Dyspnea is assessed with the modified Medical Research Council (mMRC) dyspnea scale. As the score increases, shortness of breath increases.
Clinical symptoms — Baseline The COPD Assessment Test will be evaluated. This scale scored on a 0-5 point scale to assess symptoms associated with COPD. As the score increases, the symptom increases.
Trial sites (1)
Facility
City
Region
Status
Karabuk University, Physiotherapy and Rehabilitation Application and Research Center
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.